Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
Semorinemab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names MTAU-9937A, RG-6100, RO-7105705) is a monoclonal antibody against tau which was under development for the treatment of Alzheimer's disease but was discontinued. It binds to the N-terminus of all six isoforms of tau. The drug was ineffective in the treatment of Alzheimer's disease in two phase 2clinical trials. Clinical development of semorinemab for Alzheimer's disease was discontinued in February 2024.
^ Penny LK, Lofthouse R, Arastoo M, Porter A, Palliyil S, Harrington CR, et al. (May 2024). "Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease". Translational Neurodegeneration. 13 (1): 25. doi:10.1186/s40035-024-00417-w. PMC11107038. PMID38773569. Tis has led to a number of frst-generation tau-targeting immunotherapies targeting the N-terminus such as semorinemab , tilavonemab , zagotenemab and gosuranemab . However, these antibodies achieved negative outcomes in AD and primary tauopathy clinical trials, showing lack of efcacy and missing their primary endpoints. An exception is semorinemab which, in one of the two phase 2 trials, improved cognitive function (one of the co-primary endpoints) without afecting the activities of daily living or any of the prespecifed secondary outcomes . Tese negative outcomes were achieved despite clear evidence of target engagement, with N-terminal tau decreasing in CSF and increasing in plasma. In the most extreme example, gosuranemab decreased N-terminal tau in CSF by 98% (11% increase for placebo) without showing clinical efcacy in progressive supranuclear palsy (PSP).
